Enrollment begins for cataract surgery pain trial

Patient enrollment has begun in a phase III clinical trial of a low dose of bromfenac delivered via a synthetic polymer-based formulation designed to extend the residence time of a drug (BromSite, InSite Vision) for the reduction of pain and inflammation after cataract surgery.

Full Story →